Pharmacokinetic Analysis of Nutrient Absorption From a Novel Liposomal Multivitamin/Mineral Formulation
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Texas
-
Lubbock, Texas, United States, 79409
- Department of Kinesiology & Sport Management
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- age 18 to 65 at time of consent
- ability to comply with study procedures
- availability to complete study based on durations of individual visits and scheduling requirements
- body mass of at least 110 pounds
Exclusion Criteria:
- failure to meet any of the aforementioned inclusion criteria
- presence of a disease or medical condition that could reasonably influence study outcomes or make participation inadvisable
- use of medication that could reasonably influence study outcomes or make participation inadvisable
- inability to abstain from medication, supplement, or substance use during the overnight fast and duration of the study visit
- anticipated inability to provide blood samples (e.g., known difficulty providing blood samples)
- currently pregnant or breastfeeding, based on self-report
- allergy that would prevent safe consumption of standardized breakfast or multivitamin product
Study Plan
How is the study designed?
Design Details
- Primary Purpose: OTHER
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: TRIPLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: Liposomal multivitamin/mineral condition
Ingestion of novel, liposomal multivitamin/mineral.
|
Two-capsule dose of liposomal multivitamin/mineral that is nutrient-matched to the standard multivitamin/mineral.
|
|
ACTIVE_COMPARATOR: Standard multivitamin/mineral condition
Ingestion of standard multivitamin/mineral.
|
Two-capsule dose of standard multivitamin/mineral that is nutrient-matched to the liposomal multivitamin/mineral.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Iron
Time Frame: The AUC value will be calculated using data from four time points: immediately prior to multivitamin/mineral ingestion and 2, 4, and 6 hours after ingestion of multivitamin/mineral.
|
Area under the concentration vs. time curve (AUC) for iron in serum
|
The AUC value will be calculated using data from four time points: immediately prior to multivitamin/mineral ingestion and 2, 4, and 6 hours after ingestion of multivitamin/mineral.
|
|
Iron
Time Frame: The Cmax value will be determined as the highest concentration observed from four time points: immediately prior to multivitamin/mineral ingestion and 2, 4, and 6 hours after ingestion of multivitamin/mineral.
|
Maximal concentration (Cmax) of iron in serum
|
The Cmax value will be determined as the highest concentration observed from four time points: immediately prior to multivitamin/mineral ingestion and 2, 4, and 6 hours after ingestion of multivitamin/mineral.
|
|
Magnesium
Time Frame: The AUC value will be calculated using data from four time points: immediately prior to multivitamin/mineral ingestion and 2, 4, and 6 hours after ingestion of multivitamin/mineral.
|
Area under the concentration vs. time curve (AUC) for magnesium in serum
|
The AUC value will be calculated using data from four time points: immediately prior to multivitamin/mineral ingestion and 2, 4, and 6 hours after ingestion of multivitamin/mineral.
|
|
Magnesium
Time Frame: The Cmax value will be determined as the highest concentration observed from four time points: immediately prior to multivitamin/mineral ingestion and 2, 4, and 6 hours after ingestion of multivitamin/mineral.
|
Maximal concentration (Cmax) of magnesium in serum
|
The Cmax value will be determined as the highest concentration observed from four time points: immediately prior to multivitamin/mineral ingestion and 2, 4, and 6 hours after ingestion of multivitamin/mineral.
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- 2021-527
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mineral Absorption
-
NCT00868738CompletedMineral Absorption
-
NCT01177917CompletedMineral Absorption in the Urine
-
NCT06327529RecruitingIron Absorption | Zinc Absorption
-
NCT06042985Not yet recruitingCalcium Citrate Absorption | Calcium Carbonate Absorption
-
NCT01185769Completed
-
NCT04290312Completed
-
NCT05032807Completed
Clinical Trials on Liposomal multivitamin/mineral
-
NCT06666660Recruiting
-
NCT07433049RecruitingBody Composition | Mental Health | Glucose Control | Musculoskeletal Health
-
NCT07242430RecruitingPerimenopause | Perimenopause, Climacteric Syndrome | Perimenopausal Women
-
NCT07622147Not yet recruitingMeningitis | Primary Prevention | Primary Prevention/Methods | Respiratory Tract Infections (RTI) | Immuno-monitoring | Immuno-modulation | Mitochondrial Biomarkers
-
NCT00001077CompletedHIV Infections | HIV Wasting Syndrome
-
NCT01125163Completed
-
NCT04551339CompletedHealthy | Aging | Health Care Worker Patient Transmission
-
NCT03212092CompletedAggression | Intellectual Disability